Projects Currently in Analysis and Publication

The Collaboration to Advance Negative Symptom Assessment in Schizophrenia (CANSAS)

The purpose of this study was to construct a next-generation, valid and reliable negative symptom scale for patients diagnosed with schizophrenia.

  • Principal Investigator: Raquel E. Gur, M.D., Ph.D.
  • Study Contact: Amy Cassidy
Consortium on the Genetics of Schizophrenia (COGS-2)

The principal objective of this study is to examine the genetic basis of impairments in core neuropsychological and neurocognitive processes in schizophrenia patients.

  • Principal Investigator: Raquel Gur, M.D
  • Study Contact: Amy Cassidy
Functional Neuroimaging of Reward and Motivation Deficits in Schizophrenia (DAY2)

The overall goal of the study is to relate neural activity in reward-motivation circuits to specific negative symptoms of schizophrenia.

Functional Neuroimaging of Decision-Making and Reward Valuation Across Psychiatric Disorders (FNDM)

This study aims to better understand the reward and motivation system of the brain and how brain activity can change in people with bipolar disorder and major depression.

Neurobiology of Affective Dysfunction - Emotion Expression Study (FACES)

The purpose of this study is to assess affective flattening and blunting in patients at clinical or genetic risk for developing schizophrenia, with schizophrenia, and healthy controls.

  • Principal Investigator: Christian Kohler, M.D.
  • Study Contact: Jeff Valdez, MS
The Neurobiology of Affective Dysfunction in Schizophrenia (AFFECT)

The purpose of this study is to examine neural response facial affect in patients diagnosed with schizophrenia or schizoaffective disorder, as compared to healthy siblings of schizophrenia patients, and to healthy controls from the general population.

  • Principal Investigator: Raquel Gur, M.D. and Ruben Gur, Ph.D.
  • Study Contact: Jeff Valdez, MS
Multiplex Genetic Initiative (MGI2)

The study is designed to obtain data for testing hypotheses on genetic liability to schizophrenia.

Olfactory Function in Schizophrenia: A Lifespan Analyis (OlfLifespan)

The objective of this study is to examine the neurodevelopmental contributions to chemosensory dysfunction in patients.

A Prospective Study of Endophenotypes in At-Risk Youths and Their Siblings (NAYA-K)

The purpose of this study is to obtain baseline clinical measures in youths (ages 10-25) with psychotic disorders, and those at risk for the development of a psychotic disorder in comparison to age matched healthy volunteers.

The Neurobiology of Affective Dysfunction in Schizophrenia (AFFECT)

The purpose of this study is to examine neural response facial affect in patients diagnosed with schizophrenia or schizoaffective disorder, as compared to healthy siblings of schizophrenia patients, and to healthy controls from the general population.

  • Principal Investigator: Raquel Gur, M.D. and Ruben Gur, Ph.D.
  • Study Contact: Jeff Valdez, MS
Schizophrenia Liability Genes Among African Americans
(PAARTNERS: Project among African Americans to Explore Risks for Schizophrenia)

The primary objective of this study, sponsored by NIMH, was to identify genetic influences on cognitive abilities among African American families, all of whom had at least one member affected by schizophrenia. The core project also examined genetic influences on cognitive abilities among persons affected by schizophrenia and their extended family members. This study was a collaboration of eight clinical sites and recruited a sample of 1260 African American families. The recruiting sites were the University of Alabama at Birmingham, Duke University, Morehouse School of Medicine, the University of Mississippi Medical Center, the University of Tennessee-Memphis, the University of Pennsylvania, the University of Pittsburgh, and the Medical University of South Carolina.

Consortium on the Genetics of Endophenotypes in Schizophrenia: COGS-1

This study was a multi-site collaboration that examined the genetic architecture of quantitative endophenotypes in families with schizophrenia. The seven participating sites were Harvard University, Mount Sinai School of Medicine, University of California Los Angeles, University of California San Diego, University of Colorado, University of Pennsylvania, and University of Washington.


Back to Top